

PRESS RELEASE

CELLECTIS ISSUES STATEMENT REGARDING PATENT SUITS ON MEGANUCLEASE TECHNOLOGY

Paris (France), October 3, 2011: Collectis SA (Alternext: ALCLS), the French genome engineering company, provided an update today regarding its recent patent litigations against Precision Biosciences, Inc. ("Precision"). On November 30th 2010, in the District of Delaware, Collectis brought suit against Precision for infringement of Collectis's U.S. Patent No. 7,842,489. Shortly thereafter, on March 1st, 2011, Collectis brought a second suit against Precision for infringement of Collectis's U.S. Patent No. 7,897,372, also filed in the District of Delaware. In a related matter to Collectis's suits against Precision for infringement, Precision filed suit last week against Collectis in the Eastern District of North Carolina, alleging infringement of its U.S. Patent No. 8,021,867 ("the '867 patent").

Collectis believes that the claims of the '867 patent are invalid. Collectis also believes that this patent is too narrow to cover its meganucleases and, therefore, should not interfere with Collectis continuing its business of making, using and selling such meganucleases.

Consistent with this belief and to counter the allegations made in Precision's suit on the '867 patent, Collectis also filed a new suit last week in the District of Delaware, seeking a declaration that Precision's '867 patent is invalid and not infringed by Collectis.

Importantly, Collectis will continue its robust leadership efforts in the meganuclease business and vigorously enforce its intellectual property rights, including through actions such as those above.

About Collectis

Collectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Collectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. More information at: www.collectis.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

Collectis

+33 (0)1 41 83 99 00

media@collectis.com